"Pharmacogenomic Testing" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The detection of genetic variability (e.g., PHARMACOGENOMIC VARIANTS) relevant to PHARMACOGENETICS and PRECISION MEDICINE. The purpose of such genetic testing is to help determine the most effective treatment options and their optimum dosages with least potential risks for DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS.
| Descriptor ID |
D000071185
|
| MeSH Number(s) |
E01.370.225.562.500 E05.200.562.500 E05.393.435.500 N02.421.308.430.500 N02.421.726.233.221.500
|
| Concept/Terms |
Pharmacogenomic Testing- Pharmacogenomic Testing
- Pharmacogenomic Testings
- Pharmacogenomic Screening
- Pharmacogenomic Screenings
- Pharmacogenetic Screening
- Pharmacogenetic Screenings
- Pharmacogenetic Testing
- Pharmacogenetic Testings
Pharmacogenomic Analysis- Pharmacogenomic Analysis
- Pharmacogenomic Analyses
- Pharmacogenetic Study
- Pharmacogenetic Studies
- Studies, Pharmacogenetic
- Pharmacogenetic Analysis
- Pharmacogenetic Analyses
- Pharmacogenomic Study
- Pharmacogenomic Studies
|
Below are MeSH descriptors whose meaning is more general than "Pharmacogenomic Testing".
Below are MeSH descriptors whose meaning is more specific than "Pharmacogenomic Testing".
This graph shows the total number of publications written about "Pharmacogenomic Testing" by people in this website by year, and whether "Pharmacogenomic Testing" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 0 | 1 |
| 2017 | 1 | 0 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
| 2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Pharmacogenomic Testing" by people in Profiles.
-
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. JAMA. 2022 07 12; 328(2):151-161.
-
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine. Antimicrob Agents Chemother. 2019 04; 63(4).
-
Genetic polymorphisms in candidate genes are not associated with increased vincristine-related peripheral neuropathy in Arab children treated for acute childhood leukemia: a single institution study. Pharmacogenet Genomics. 2018 08; 28(8):189-195.
-
Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. Pharmacogenomics. 2017 Apr; 18(6):555-570.
-
Impressions of pharmacogenomic testing among Certified Registered Nurse Anesthetists: a mixed-method study. Pharmacogenomics. 2016 04; 17(6):593-602.